IP Library Granted Patent US 9,957,487
Granted Patent B2
US 9,957,487 · App. 14/516,666 · Granted May 1, 2018

Mutated genes for the catalytic protein of

Inventors: Satoshi Inouye (Kanagawa, JP); Junichi Sato (Kanagawa, JP)
Assignee: JNC CORPORATION
C12N9/0069C07K14/43509C12Q1/66C12Y113/12007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,957,487
App. No.
14/516,666
Granted
May 1, 2018
Kind
B2
Abstract

Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.

Claims (14)

1. A luciferase mutant defined in (a) or (b) below:

(a) a luciferase mutant comprising the amino acid sequence of SEQ ID NO: 2 substituted at the positions consisting of the valine at position of 44, the alanine at position 54, and the tyrosine at position 138, wherein the luciferase mutant has luciferase activity; and

(b) a luciferase mutant comprising the amino acid sequence of SEQ ID NO: 2 substituted at the positions consisting of:

(1) the valine at position of 44, the alanine at position 54, and the tyrosine at position 138; and

(2) one to sixteen positions, none of which includes any one of the positions 4, 11, 18, 27, 33, 43, 68, 72, 75, 90, 115, 124, and 166, wherein the luciferase mutant has luciferase activity.

2. The luciferase mutant according to claim 1 , wherein the luciferase mutant comprises the amino acid sequence of SEQ ID NO: 2 substituted at the positions consisting of:

(1) the valine at position of 44, the alanine at position 54, and the tyrosine at position 138; and

(2) one to ten positions, none of which includes any one of the positions 4, 11, 18, 27, 33, 43, 68, 72, 75, 90, 115, 124, and 166.

3. The luciferase mutant according to claim 1 , wherein the valine at position 44 is substituted by an isoleucine, the alanine at position 54 is substituted by an isoleucine, and the tyrosine at position 138 is substituted by an isoleucine.

4. The luciferase mutant according to claim 1 , comprising the amino acid sequence of SEQ ID NO: 16.

5. A kit comprising the luciferase mutant according to claim 1 .

6. The kit according to claim 5 , further comprising a luciferin.

7. The kit according to claim 6 , wherein the luciferin is coelenterazines.

8. The kit according to claim 7 , wherein the coelenterazines is coelenterazine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2023
From: JNC CORPORATION
To: PROLUME LTD.
Reel/Frame 063962/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2014
From: INOUYE, SATOSHI; SATO, JUNICHI
To: JNC CORPORATION
Reel/Frame 033970/0659 →
Priority Claims (1)
JP 2013-218111 · Oct 21, 2013 · national
Continuity (1)
Related Publication 20150111233A1 · Apr 23, 2015